PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
16.61%
Positive net income growth while Biotechnology median is negative at -3.02%. Peter Lynch would view it as a strong advantage vs. struggling peers.
4.17%
D&A growth of 4.17% while Biotechnology median is zero at 0.00%. Walter Schloss would question intangible or new expansions driving that cost difference.
-100.00%
Deferred tax shrinks yoy while Biotechnology median is 0.00%. Seth Klarman would see potential advantage if actual tax outflows do not spike.
-2.08%
SBC declines yoy while Biotechnology median is 1.84%. Seth Klarman would see a near-term advantage in less dilution unless new hires are needed.
-115.45%
Working capital is shrinking yoy while Biotechnology median is -52.09%. Seth Klarman would see an advantage if sales remain robust.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-138.13%
AP shrinks yoy while Biotechnology median is 0.00%. Seth Klarman would see better immediate cost coverage if top-line remains intact.
-68.80%
Other WC usage shrinks yoy while Biotechnology median is -23.23%. Seth Klarman would see an advantage if top-line is stable or growing.
119.47%
Growth of 119.47% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or one-off revaluations explaining the difference.
9.84%
Positive CFO growth while Biotechnology median is negative at -19.98%. Peter Lynch would see a notable cash advantage in a challenging sector environment.
98.37%
CapEx growth of 98.37% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or upgrades behind the difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
98.37%
Investing flow of 98.37% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or deals prompting that difference.
64.41%
Debt repayment growth of 64.41% while Biotechnology median is zero at 0.00%. Walter Schloss wonders if expansions or a shift in capital structure drive that difference.
-34.38%
We reduce issuance yoy while Biotechnology median is 0.00%. Seth Klarman might see an advantage in preserving per-share value unless expansions are neglected.
No Data
No Data available this quarter, please select a different quarter.